Teprotumumab significantly reduces extraocular muscle cross-sectional area in thyroid eye disease
After treatment with teprotumumab in patients with thyroid eye disease (TED), extraocular muscle (EOM) cross-sectional areas (CSA) is significantly reduced, according to a study.
In this retrospective study, pre- and post-teprotumumab treatment CT imaging of 48 orbits of 24 patients with thyroid eye disease were evaluated by 2 radiographic reviewers for EOM CSA measurements.
There was a significant reduction before and after treatment in the total EOM to orbit CSA and of each individual muscle group to orbit CSA. In 87.5% of patients, total EOM to orbit CSA ratios were reduced, and in 54.2% of those patients, it was statistically significant. Significant improvements in clinical activity score, proptosis, diplopia, and EOM motility were noted for all categories.
There was a significant correlation between the reduction of EOM CSA and the reduction of diplopia and EOM motility.
Reshef ER, Marsiglia M, Bouhadjer K, et al. Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2023;e002337. doi: 10.1097/IOP.0000000000002337. Epub ahead of print. PMID: 36852831.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809